Trial Profile

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity: A Randomized Pragmatic Trial

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Ustekinumab (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms CONDOR

Most Recent Events

01 Aug 2022 Results (n=118) assessing of serum drug concentrations, ADA levels, and predictors for successful dose reduction of adalimumab, ustekinumab, and etanercept for psoriasis published in the Journal of Dermatological Treatment
28 Jun 2022 Results (n=40) assessing population pharmacokinetics and pharmacodynamics of ustekinumab in patients with psoriasis, presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022.
18 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com